November 13, 2026

For Immediate Release

Company name: Kitazato Corporation
Representative: Futoshi Inoue
President, CEO
(Code number: 368A, TSE Prime)
Contact: Masanobu Suzuki
Director, General Manager of
Corporate Planning Department
(Tel. +81-545-65-7122)

Kitazato Establishes Subsidiary to Enhance its Communication Capabilities of the Group

Kitazato Corporation (“Kitazato”; TSE: 368A) announces that it has resolved to establish a wholly owned subsidiary FertiLink Co., Ltd. (tentative name).
Kitazato also announces that, as the amount of the capital of the subsidiary will be equivalent to 10% or more of Kitazato’s capital, the new subsidiary will qualify as a specified subsidiary of Kitazato.

1. Purpose of establishment

Under its Medium-Term Management Plan (fiscal years ending March 2027 through March 2029), the Company has identified “strengthening its information dissemination capabilities” as one of its key policies and is implementing initiatives to achieve this objective.

The Company also recognizes that a gap exists between people’s aspirations to have children and actual pregnancy and childbirth outcomes, and that insufficient information and understanding of reproductive medicine are among the barriers to accessing appropriate medical care.

The establishment of the subsidiary aims to address these social challenges and advance the Medium-Term Management Plan. The Company positions the new subsidiary as an organization dedicated to fostering a society in which people who wish to have children can fulfill their aspirations through accurate knowledge and appropriate medical care. Its activities will include patient education and awareness initiatives as well as the planning and management of academic conferences and seminars. Through collaboration with healthcare professionals and other companies in the industry, it will also seek to deepen understanding of fertility treatment and improve access to appropriate medical care.

With the establishment of FertiLink Co., Ltd. (tentative name) as a starting point, the Company will address these social challenges through such activities while seeking to broaden the fertility treatment market over the medium to long term and support sustainable business growth across the Group.

2. Overview of the Subsidiary

Name	FertiLink Co., Ltd. (tentative name)
Location	1-1-8 Shibadaimon, Minato-ku, Tokyo, Japan
Name and title of representative	Emi Abe, Director (candidate)
Business description	・Information provision, public awareness and education concerning reproductive medicine, fertility, and healthcare. ・Planning, organizing, managing and undertaking academic conferences, research meetings, lectures, seminars and other medical and academic events, etc.
Capital	JPY 3 million

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

Date of establishment	December 2026 (planned)	
Major Shareholder and shareholding ratio	Kitazato Corporation 100%	
Fiscal year-end	March 31	
Relationships with Kitazato	Capital	Wholly-owned subsidiary of Kitazato
	Personnel	An employee of Kitazato is expected to concurrently serve as a director of the subsidiary.
	Business	Not applicable, as the company will be newly established.

(Note) The name of the new company is provisional. Any changes will be announced separately.

3. Schedule

Date of Board of Directors resolution	November 13, 2026
Date of Establishment	December 2026 (planned)

4. Future outlook

The impact of this matter on Kitazato's consolidated financial results for the fiscal year ending March 31, 2027 is expected to be immaterial. The Company will promptly disclose any matters requiring further disclosure should they arise.

–END–

About Kitazato

Kitazato aims to help as many people as possible realize their hopes of parenthood, contributing to addressing the social challenge of declining birth rates and creating social value for a sustainable future by confronting the challenges faced by people seeking fertility treatment and healthcare professionals and providing reliable technologies.

Kitazato specializes in assisted reproductive technologies, including artificial insemination, in vitro fertilization, cell cryopreservation, and regenerative medicine. To meet the global demand for reproductive medicine, Kitazato develops and manufactures products used in fertility treatment and supplies them to approximately 110 countries and regions.

Kitazato is committed to “advancing reproductive medicine.” To fulfill this commitment, we collaborate with physicians and researchers around the world, leveraging our long-standing expertise and knowledge to improve existing technologies and develop new ones.

For more information, please visit https://www.kitazato.co.jp/en/